According to AlphaMoat, in October 2026 Alchemab Therapeutics (alchemab.com) received 2,668 monthly visits (-31.5% MoM) — ranked #14,367 of 17,609 AI websites with traffic data, and #2,437 of 3,112 in Industry Services; its largest market is UK (94.2% of visits).
Alchemab Therapeutics leverages the protective principles of the adaptive immune system, analyzing the antibody repertoires of disease-resistant individuals—such as long-term cancer survivors—to discover and develop a new generation of human-derived therapeutic antibodies.
| Month | Monthly visits | MoM |
|---|---|---|
| 2026-06 | 2.9K | — |
| 2026-07 | 4.6K | +60.0% |
| 2026-08 | 2.5K | -46.3% |
| 2026-09 | 3.9K | +57.2% |
| 2026-10 | 2.7K | -31.5% |
An AI recruiting platform unifying hiring workflows, talent relationships, and analytics.
+ CompareA platform connecting specialists with model research, training, and evaluation projects
+ CompareA conversational hiring agent that moves candidates from application through onboarding
+ CompareA talent-intelligence platform using agents to support hiring, development, and workforce deployment
+ CompareA clinician platform combining communication, telehealth, and AI-assisted documentation
+ CompareAn AI research and search platform built for professional investors
+ CompareAccording to AlphaMoat, Alchemab Therapeutics (alchemab.com) received 2,668 visits (about 2.7K) in October 2026 (-31.5% month over month), ranking #14,367 of 17,609 AI websites with traffic data, and #2437 in Industry Services.
In October 2026, Alchemab Therapeutics’s largest markets by share of visits are UK 94.2%, United States 5.8%.
In Industry Services, the other products with the most monthly visits are Ashby (28.4M), Mercor (14.2M), Paradox (11.4M), Eightfold AI (11.0M), Doximity (10.0M).
Data month: 2026-10 · Visit figures are third-party traffic estimates aggregated monthly — best for scale and trends. Multiple domains of the same product are merged. See methodology.